Gilbert Bigras

2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests

Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studies

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ki67 assessment in breast cancer: an update

Prevalence of Oral HPV Infection in the United States, 2009-2010

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Age-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global Review

Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Sexually Transmitted Diseases Treatment Guidelines, 2010

Dissemination and publication of research findings: an updated review of related biases

Model for Assessing Human Papillomavirus Vaccination Strategies

Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13 842 women

Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study